期刊文献+

生物陶瓷材料的应用及其发展前景 被引量:20

Applications of bioceramics and its future
原文传递
导出
摘要 生物陶瓷由于具有良好的生物相容性与骨传导性,能与细胞等生物组织表现出良好的亲和性,因此具有广阔的发展前景。它作为生物硬组织的代用材料,可用于骨科、整形外科、牙科、口腔外科、心血管外科、眼外科、耳鼻喉科及普通外科等方面。本文介绍生物陶瓷的分类、生物学特性及其在医用领域的应用,并展望其未来十年发展方向。根据与生物组织的作用机制,生物陶瓷大致可分为生物活性陶瓷、生物惰性陶瓷。生物活性陶瓷主要介绍羟基磷灰石(HA)的特性和其复合材料及其在硬组织工程中的应用。包括纳米HA胶/原复合材料及通过复合卵磷脂、生长因子和细胞等来提高材料的生物活性。本文也简单说明了生物活性玻璃和磷酸三钙的特性与应用现状。生物惰性陶瓷主要介绍了临床广泛应用的氧化铝陶瓷和氧化锆陶瓷的生物学特性。 Bioceramics,because of their advantages of biocompatibility,osteoconduction,and biological affinity,it has become a potential useful material for biological scleroses tissues in terms of orthopedics,plastic surgery,dental surgery,oral surgery,cardiovascular surgery,ophthalmic surgery,otorhinolaryngology and general surgery.In this article,we introduce the classification,biological feature and practical applications of bioceramics on medicine,and prospect the development of bioceramics in the coming 10 years.According to the action mechanism of the materials with tissues,bioceramics can be divided into active bioceramics and inactive bioceramics.Active bioceramics mainly recommend hydroxyapatite ceramic.Its applications in hard tissue engineering,including blending lecithin or growing factors or cells to improve biological activity are reviewed.Moreover the characteristics and applications of bioactive glass and tricalcium phosphate are illustrated.On inactive bioceramics the biological characteristics and advantages of aluminum oxide ceramics and zirconium oxide ceramics are introduced.
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第7期1343-1347,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 生物陶瓷 羟基磷灰石 骨组织工程 生长因子 Bioceramics hydroxyapatite bone tissue engineering growing factor
  • 相关文献

参考文献4

二级参考文献21

  • 1[1]Sonntag VKH, Marciano FF. Is fusion indicated for lumbar spinal disorders? Spine 1995; 20:138s- 142s 被引量:1
  • 2[2]Boden SD, Schimandle JH, Hutton WC, et al. 1995 Volvo Award in Basic Science: the use of an osteoinductive growth factor for lumbar spinal fusion. Part Ⅰ: biology of spinal fusion.Spine 1995; 20:2626-2632 被引量:1
  • 3[3]Boden SD, Schimandle JH, Hutton WC. 1995 Volvo Award in Basic Science: the use of an osteoinductive growth factor for lumbar spinal fusion. Part Ⅱ: study of dose, carrier, and species.Spine 1995; 20:2633-2644 被引量:1
  • 4[4]Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma 1989; 3:192-195 被引量:1
  • 5[5]Cook SD, Dalton JE, Tan EH, et al. In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine 1994; 19:1655-1663 被引量:1
  • 6[6]Boden SD, Schimandle JH, Hutton WC. An experimental Lumbar intertransverse process spinal fusion model. Spine 1995a;20:412-420 被引量:1
  • 7[7]Sandhu HS, Kanim MA, Toth JM, et al. Experimental spinal fusion with recombinant human bone morphogenetic protein-2without decortication of osseous elements. Spine 1997; 22:1171-1180 被引量:1
  • 8[8]Lowenstam HA, Weiner S. On biomineralization. New York:Oxford University Press; 1989, p35-40. 被引量:1
  • 9[9]Landis WJ, Song M J, Leith A, et al. Mineral and organic matrix interaction in normally calcifying tendon visualized in three dimensions by high-voltage electron microscopic tomography and graphic image reconstruction. J Struct Bio11993; 110:39-54 被引量:1
  • 10[10]Du C, Cui FZ, Zhang W, et al. Formation of calcium phosphate/collagen composites through mineralization of collagen matrix. J Biomed Mater Res 2000; 50:518-527. 被引量:1

共引文献78

同被引文献277

引证文献20

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部